Evaluating the Role of CCL20 in Prostate Cancer Progression
Corresponding Organization : Nanjing Medical University
Other organizations : Southern Medical University, Nanfang Hospital, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Yancheng First People's Hospital, Third Affiliated Hospital of Southern Medical University
Variable analysis
- Conditioned medium (CM) from TAMs (co-cultured with PCa cells)
- Human recombinant CCL20 protein (rh-CCL20, 20 ng/ml)
- Neutralizing antibody to CCL20 (anti-CCL20, 5 μg/ml)
- Cell proliferative rate (assessed using the Cell Counting Kit-8)
- Cell migration (stable cell lines treated with or without 5 μg/ml CCL20 neutralizing antibody)
- Cell invasion (CM of TAMs placed in the lower chamber as an attractor for PCa cell invasion)
- PCa cells stably transfected
- Medium containing 10% FBS in the lower chamber
- Positive control: Medium containing 10% FBS in the lower chamber
- Negative control: Medium without 20 ng/ml CCL20 recombinant protein in the lower chamber
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!